Mergers & Acquisitions ·
On September 11, 2026, AtaiBeckley Inc. completed its merger with Eli Lilly and Company via Albali Acquisition…
ATAIAtaiBeckley Inc.
On September 11, 2026, AtaiBeckley Inc. completed its merger with Eli Lilly and Company via Albali Acquisition Corporation, becoming a wholly owned subsidiary of Parent. Each outstanding share of common stock was converted into $6.75 in cash plus one contingent value right (CVR). CVRs provide potential additional cash payments up to $2.50 per share based on clinical and regulatory milestones for VLS-01 and BPL-003 within specified timeframes. Equity awards were settled or cancelled accordingly, and the company's board of directors and executive officers resigned while new appointees from Parent assumed leadership roles. The company requested delisting from Nasdaq and intends to file Form 25 and Form 15 to terminate reporting obligations. AtaiBeckley Inc. operates in the biotechnology industry, focusing on psychedelic medicine development.